Status:
TERMINATED
G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)
Lead Sponsor:
AstraZeneca
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Brief Summary
This is a long-term safety follow-up study to assess the post-treatment safety, at 12 and 24 months, in patients with type 2 diabetes after participation in the phaseII/III studies GALLANT, GALLEX and...
Eligibility Criteria
Inclusion
- Provision of a written informed consent
- Men or women who either completed at least 6 months in a previous treatment study GALLANT, GALLEX or ARMOR or met a pre-defined laboratory or clinical finding during participation in any of the said studies.
Exclusion
- Received open-label treatment with tesaglitazar (since this is a post-treatment study)
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
End Date :
December 1 2006
Estimated Enrollment :
4500 Patients enrolled
Trial Details
Trial ID
NCT00255645
Start Date
September 1 2005
End Date
December 1 2006
Last Update
March 17 2008
Active Locations (543)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States
2
Research Site
Columbiana, Alabama, United States
3
Research Site
Mobile, Alabama, United States
4
Research Site
Chandler, Arizona, United States